FindTrial
Sign In

Adherence and Influencing Factors of CDK4/6 Inhibitors Plus Endocrine Therapy in Patients with HR+/HER2- Early Breast Cancer: A Real-World Retrospective Analysis

Adherence and Influencing Factors of CDK4/6 Inhibitors Plus Endocrine Therapy in Patients with HR+/HER2- Early Breast Cancer: A Real-World Retrospective Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126682
Enrollment
Unknown
Registered
2026-06-13
Start date
2026-06-14
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Grouping based on the type of CDK4/6 inhibitors :None

Sponsors

Jilin University-China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Early-stage breast cancer with HR+ and HER2- confirmed by pathology; 2. Meets the high-risk factor criteria defined by NCCN guidelines; 3. Received Abemaciclib or Ribociclib combined with endocrine therapy during the adjuvant treatment stage; 4. Aged >=18 years.

Exclusion criteria

Exclusion criteria: 1. Metastatic breast cancer; 2. Severe liver and kidney dysfunction; 3. Complicated with other malignant tumors; 4. Incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
Compliance;—

Secondary

MeasureTime frame
Adverse reaction;Quality of life;—

Countries

China

Contacts

Public ContactWan Wang

Department of Breast Surgery, China-Japan Union Hospital of Jilin University

wwan@jlu.edu.cn+86 431 8499 5047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026